Introduction to LabCentral – the new way of building biotech companies
12 October 2016 12:00 to 13:00 EDT
220 Mass. Avenue, Cambridge MA - USA
Speaker: Johannes Fruehauf, MD, PhD Founder, President and Executive Director of LabCentral
Seminar Abstract: The bio-pharmaceutical industry is undergoing significant change, part of which is a re-arrangement to a distributed model of innovation. Boston/Cambridge is a fertile ground for early stage academic innovation in biosciences and pharma, and is the leading place for entrepreneurial startup creation in this space. LabCentral addresses a key issue for academic founders: we provide fully functional laboratory spaces and co-working environment that enables innovators to meet milestones quickly and efficiently. This allows them to create value in a much more capital-efficient way and brings them in close proximity with partners on the big-pharma side of the equation through our sponsorship model.
Entry instructions: There is no cost to attend the seminar. If you are interested in attending please contact Meghan Spencer. Please check in with security at the Novartis visitor's entrance of 220 Massachusetts Avenue and you will be directed to the location of the seminar.
Johannes Fruehauf image
Speaker | Johannes Fruehauf, MD, PhD
Dr. Fruehauf is a physician-scientist and life science entrepreneur. He is the Founder, President and Executive Director of LabCentral, the largest co-working space for life-science companies in the Boston area. LabCentral is currently home to 29 high-potential startup companies and has graduated 5 companies. Companies at LabCentral have raised over $960M since its opening in 2014. LabCentral was built around a concept of openness, transparency and shared resources that helps to accelerate the growth and increases the likelihood of success for science-based companies.
Dr. Fruehauf is the Founder and CEO of Cambridge Biolabs, a service-provider to venture capital funds and startup companies in Kendall Square, which offers scientific due diligence pre-investment as well as pre-clinical CRO services to startups. Biolabs is expanding nationally and will open similar co-working facilities in all of the major research hubs, starting with San Francisco, San Diego, New York City and Durham NC. Previously, he was a co-founder and Head of R&D at Cequent Pharmaceuticals, VP of R&D at Aura Biosciences, Co-founder at Vithera Pharmaceuticals and Deltix. He is Managing Director for Bio-Innovation, a seed and early stage investment fund in the Boston area.
Dr. Fruehauf studied Medicine in Germany and France. He practiced medicine (internal medicine and OB/Gyn) for several years in Germany before coming to Boston for a post-doc at Beth Israel Deaconess Medical Center/Harvard Medical School. He is an author of 30 peer reviewed articles in the medical literature and inventor on a handful of issued and numerous pending patents, mostly on drug delivery and RNAi technologies.